 Lung cancer,41
 NSCLC,28
 Non-small cell lung cancer,26
 non-small cell lung cancer,17
 Prognosis,14
 metastasis,12
 Surgery,10
 cancer,10
PubChem CID,10
 Cancer,9
Chemotherapy,9
EGFR,9
cancer,9
 chemotherapy,9
 lung,8
Lung cancer,8
NSCLC,7
 Immunohistochemistry,7
 apoptosis,7
 immunohistochemistry,7
 Non-small-cell lung cancer,7
 Apoptosis,7
 Survival,7
 Radiotherapy,6
 Lung,6
Cancer,6
 non-small-cell lung cancer,6
 survival,6
 radiotherapy,6
 Erlotinib,5
 overall survival,5
 Gefitinib,5
 siRNA,5
 Metastases,5
 proliferation,4
 p53,4
Anaplastic lymphoma kinase,4
 STAT3,4
 NF-κB,4
Apoptosis,4
 MTT,4
 Lung adenocarcinoma,4
 Quality of life,4
 Epidermal growth factor receptor,4
 Lung resection,4
 oncology,4
 ROS,4
 Lung neoplasms,4
Acquired resistance,4
 autophagy,4
 PI3K,4
 Targeted therapy,4
 prostate cancer,4
 computed tomography,4
Angiogenesis,4
 hepatocellular carcinoma,4
Biomarker,4
 EMT,4
Breast cancer,4
 stereotactic body radiotherapy,4
 Personalized medicine,4
 Neoplasm metastasis,3
 Epidemiology,3
 Tumor,3
-2,3
 Resistance,3
EGFR-TKI,3
 confidence interval,3
 Treatment,3
 Immunotherapy,3
 SCLC,3
 Elderly,3
 Mortality,3
apoptosis,3
 HCC,3
 epidemiology,3
 palliative care,3
 cisplatin,3
 migration,3
 cell cycle,3
 biomarker,3
 neoplasms,3
 Cisplatin,3
Erlotinib,3
Cetuximab,3
 Oncology,3
 Hepatocellular carcinoma,3
3-,3
Epidermal growth factor receptor,3
 miRNA,3
5-diphenyltetrazolium bromide,3
 CI,3
 OS,3
Brain metastases,3
 reactive oxygen species,3
 Mesothelioma,3
 erlotinib,3
 Outcome,3
 Imaging,3
 surgery,3
lung cancer,3
 quality of life,3
 Metastasis,3
 Crizotinib,3
 PET/CT,3
Adenocarcinoma,3
 Chemotherapy,3
 lung adenocarcinoma,3
 Invasion,3
 Meta-analysis,3
Anticancer,3
 Lobectomy,3
 Breast cancer,3
 Positron emission tomography,3
Elderly,3
 inflammation,3
 Colorectal cancer,3
 epidermal growth factor receptor,3
 EGFR,3
PET/CT,2
 nonsmall cell lung cancer,2
 Treg,2
 Tyrosine kinase,2
1,2
 immunotherapy,2
 mental health,2
 ERK,2
 survivorship,2
 antibody-dependent cellular cytotoxicity,2
 liver,2
 Small cell lung cancer,2
 diagnosis,2
 prognosis,2
 Lung Cancer,2
MDR,2
 hormone replacement therapy,2
 Lung metastases,2
 EGFR-TKI,2
 SBRT,2
 fine-needle aspiration,2
 risk assessment,2
 PI,2
 pneumonia,2
 angiogenesis,2
 small interfering RNA,2
 MAP kinases,2
 forced expiratory volume in 1 second,2
 Migration,2
 bronchoscopy,2
 CT,2
Advanced cancer,2
 heptanal,2
 Lymph node metastasis,2
 PBS,2
breast cancer,2
 FDA,2
 drug delivery,2
 liver cancer,2
TTF-1,2
 PCR,2
 methylation,2
 Neoplasms,2
 patient-reported outcomes,2
 Predictive biomarker,2
 cisplatin resistance,2
CRC,2
 Pleural effusion,2
Chemoradiotherapy,2
 PI3K/Akt,2
 interventional pulmonology,2
 PFS,2
Meta-analysis,2
asbestos,2
 PAS,2
 myeloid-derived suppressor cells,2
 ferroptosis,2
 mesothelioma,2
 Risk factors,2
Adenocarcinoma in situ,2
 Mutation,2
 progression-free survival,2
 personalized medicine,2
 fluorescence-activated cell sorting,2
 meta-analysis,2
 nanoparticles,2
 HB-EGF,2
 DLCO,2
Acute lung injury,2
 Gene delivery,2
 colorectal cancer,2
 mTOR,2
 small cell lung cancer,2
asthma,2
 Bone metastases,2
 polymorphism,2
 RFA,2
 smoking,2
 stereotactic,2
adenocarcinoma,2
 radiation therapy,2
 osteosarcoma,2
 breast cancer,2
 RNAi,2
Cohort study,2
 gefitinib,2
 Non-small-cell lung cancer ,2
 Leukemia,2
 Interstitial lung disease,2
Atrial fibrillation,2
 smoking cessation,2
 symptom management,2
 Lung carcinoma,2
AP-1,2
 prognostic factors,2
 Gene amplification,2
 Thymic carcinoma,2
 immunocytochemistry,2
 cancer incidence,2
 crizotinib,2
 pRb,2
C-reactive protein,2
Crizotinib,2
 Nodule pulmonaire,2
 Vimentin,2
 Radiation,2
Biomarkers,2
 FEV1,2
 magnetic resonance imaging,2
 carcinogenesis,2
 pneumothorax,2
 rapid on-site evaluation,2
 polymerase chain reaction,2
Cisplatin,2
 Population-based,2
 tobacco smoking,2
 staging,2
DNA methylation,2
 Toll-like receptor,2
 propidium iodide,2
 ovarian cancer,2
bronchoscopy,2
 Non–small-cell lung cancer,2
 Staging,2
4DCT,2
 miRNAs,2
 epigenetics,2
 Computed tomography,2
 Survey,2
 non-small cell lung carcinoma,2
 PTEN,2
 O,2
 Pulmonary metastasis,2
 FACS,2
 Malignant pleural mesothelioma,2
 melanoma,2
 pemetrexed,2
 Polymerase chain reaction,2
 survivin,2
 MAPK,2
 SPECT,2
 mice,2
 radiosurgery,2
Immunohistochemistry,2
 MEK,2
 drug resistance,2
 sunitinib,2
 Tumor suppressor,2
 Small-cell lung cancer,2
 VEGF,2
 IGRT,2
 DNA methylation,2
Epidemiology,2
 Systematic review,2
 EML4-ALK fusion gene,2
angiogenesis,2
 VO,2
 resistance,2
ALK,2
 mortality,2
 asthma,2
 P-glycoprotein,2
 Exhaled breath condensate,2
 telomere length,2
 biomarkers,2
